-
Merck KGaA Reports 3.8% Organic Growth in Q3 2024 Financials
•
Merck KGaA (NYSE: MRK), the German multinational science and technology company, has released its financial results for the third quarter of 2024, reporting net sales of EUR 5.266 billion (USD 5.55 billion), marking an organic growth of 3.8%. The company’s performance reflects a steady increase in sales across its business…
-
FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo
•
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing revenues of USD 46.3 million for the quarter, a 15% year-on-year (YOY) increase. The net loss narrowed significantly to USD 17.1 million, compared to USD 63.6 million during the same period last year. As of…
-
AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials
•
UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the Q3 2024 period, showing a robust 21% year-on-year (YOY) increase in total revenues to USD 13.565 billion at constant exchange rates. Product sales also saw a significant 20% growth to USD 12.947 billion. Business Unit…
-
BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its Q3 2024 financial results, achieving total operating revenue of USD 1.002 billion, marking a 28% year-on-year (YOY) increase. Product revenue within this total saw a substantial 67% YOY rise to USD 993 million. For the…
-
Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals
•
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6% year-on-year (YOY) growth in constant currency terms to EUR 9.968 billion (USD 10.59 billion) in global group sales. This growth was driven by strong performances in the Pharmaceuticals and Consumer Healthcare segments, offsetting a decline…
-
Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial report, showcasing robust growth and providing updates on recent product highlights and corporate developments. Revenue Growth and Product PerformanceDuring Q3, Zai Lab reported product net revenues of USD 101.8 million, a 46% year-on-year (YOY) increase…
-
Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter of 2024, reporting a significant increase in revenue. The company generated USD 160 million in revenue for the three months ended September 30, 2024, marking a 67% year-on-year (YOY) increase. Revenue Breakdown and Key DriversCollaboration…
-
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
•
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the third quarter of 2024, ending September 30, 2024, along with operational updates. The company reported revenue of RMB 698 million (USD 96.9 million) for the first three quarters, marking a 29.8% increase over the same…
-
Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
•
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter of 2024, revealing a 5% year-on-year (YOY) decrease in global sales to USD 3.8 billion in constant currency terms. The report indicates that generics and brand sales fell by 2% and 6% respectively, reaching USD…
-
Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
•
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase…
-
Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth
•
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the third quarter of 2024. The company reported revenues of DKK 204.72 billion (USD 29.459 billion) for the first nine months, marking a 24% year-on-year (YOY) growth in constant currency terms. Diabetes and Obesity Care Drive…
-
Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth
•
Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the fourth quarter of fiscal 2024, ended September 30, 2024, and the full fiscal year 2024. The company achieved its targets for revenue growth and earnings per share for FY2024, demonstrating resilience amidst challenging market…
-
Fresenius Medical Care Reports 2% YOY Revenue Decrease in 2024 Q3 Financial Results
•
Germany-based Fresenius Medical Care (FRA: FMEA) has released its financial report for the third quarter of 2024. The total revenues for the quarter reached EUR 4.76 billion, marking a year-on-year (YOY) decrease of 2% in constant exchange rate terms. The operating income saw a significant rise, increasing by 43% YOY…
-
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
•
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year 2024, reporting a 5% year-on-year (YOY) increase in global revenues at constant exchange rates (CER), reaching JPY 2.38 trillion (USD 15.63 billion). The core operating profit margin expanded to 30.2%, marking a 2.2 percentage point…
-
MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector
•
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial report for the third quarter of 2024, highlighting a 4% year-on-year (YOY) increase in revenues to USD 1.67 billion. The Pharmaceutical sector experienced a 5% YOY growth, reaching USD 14.943 billion, while the Animal Health…
-
Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
•
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of 2024, with revenues reaching USD 3.72 billion, marking an 11% increase year-on-year (YOY). Product sales grew by 9% YOY to USD 1.946 billion, while collaboration revenues stood at USD 1.774 billion, up 12.5% YOY. In…
-
Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance
•
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for the third quarter of 2024, marking a 3% year-on-year (YOY) decrease in operational terms. Despite this, Biogen increased its full-year 2024 financial guidance, with non-GAAP diluted EPS now expected to range between USD 16.10 and…
-
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
•
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD 323 million) for the third quarter of 2024, marking a 40% year-on-year (YOY) increase. The company’s competitive edge in China is attributed to its product indication expansion, extensive coverage on the National Reimbursement Drug List,…
-
Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third quarter of 2024, announcing revenues of RMB 135 million (USD 18.94 million) for the quarter, marking a 236.39% year-on-year (YOY) increase. Revenues for the first three quarters reached RMB 338 million (USD 47.43 million), reflecting…
-
Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
•
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter of 2024, with revenues reaching USD 8.5 billion, an increase of 23% year-on-year (YOY). Product sales saw a 24% increase, with an 8% growth when excluding sales from the Horizon Therapeutics (Horizon) acquisition. In the…
-
Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
•
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024, reporting sales of USD 2.6 billion, reflecting a 12% year-on-year (YOY) increase in constant currency terms. Chemical generics contributed USD 1.854 billion in sales, marking a 4% YOY increase, while biosimilars saw a significant surge…
-
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
•
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter of 2024, reporting revenues of RMB 1.271 billion (USD 178.36 million) for the first three quarters, marking a 28.87% year-on-year (YOY) increase, and a net loss of RMB 927 million (USD 130 million). The third…
-
Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for the third quarter of 2024, with total revenues increasing by 20% year-on-year (YOY) to USD 11.439 billion. The growth was propelled by volume increases from Mounjaro and Zepbound, as well as higher realized prices. In…
-
GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2024, showing a modest 2% year-on-year (YOY) increase in revenue to GBP 8 billion (USD 10.496 billion) at constant exchange rates. The quarter’s performance was propelled by a 19% surge in the Specialty…
-
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
•
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter ended September 30, 2024, with net revenues of USD 14.46 billion, marking a 4.9% increase year-on-year at constant exchange rates. The US market contributed USD 11.148 billion in sales, while the International Market (excluding the…
-
Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion
•
Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion for the third quarter, a 32% year-on-year (YOY) increase at constant exchange rates. For the first nine months of the year, revenues totaled $45.864 billion, reflecting a 3% YOY growth. This strong performance has prompted…
-
Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16%…
-
Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for the third quarter of 2024, highlighting overall revenues of RMB 30.912 billion (USD 4.33 billion) for the first three quarters, marking a 5.74% year-on-year (YOY) increase excluding COVID-19 related products. The company’s revenues for…
-
Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline
•
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the third quarter of 2024, reporting a total revenue increase of 6.14% year-on-year (YOY) to RMB 209.629 billion (USD 29.42 billion). The pharmaceutical industry and pharmaceutical business segments achieved sales of RMB 18.284 billion (USD 2.56…
-
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
•
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing potential restrictions under the Biosecure Act—set to ban drugmakers with U.S. government contracts from utilizing Chinese services post-2032—reported its financial results for the first three quarters of 2024. In the third quarter, revenues reached RMB…
-
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
•
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced its financial results for the third quarter of 2024, highlighting a robust 19.5% year-on-year (YOY) increase in net sales, which reached USD 4.209 billion. The company’s business units reported significant growth, with MedSurg contributing USD…
-
Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), has released its financial report for the third quarter of 2024. The company reported revenues of RMB 939 million (USD 131.8 million) for the period, marking a 28.58% increase year-on-year. The net profit attributable to…
-
Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals
•
Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the third quarter of 2024, highlighting a robust 9.4% year-on-year sales growth in constant currency terms, reaching USD 10.64 billion. The Established Pharmaceuticals segment recorded a 2.7% rise in Q3 to USD 1.406 billion, with emerging…
-
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
•
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter of 2024, announcing revenues of USD 22.47 billion for the period, marking a 5.2% increase year-on-year in constant currency terms. This growth was comprised of USD 4.58 billion in innovative medicine sales, which expanded by…
-
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the first half of the year 2024. The company reported revenues of RMB 206 million for the period, a decrease of 41.4% year-on-year (YOY). All revenues were attributed to the direct sales of its PD-L1 monoclonal…
-
InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its financial report for the first half of 2024, highlighting a revenue of RMB 4.197 billion, marking an increase of 11.2% year-on-year. This growth was primarily driven by the rapid adoption of its key product, orelabrutinib,…
-
Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released its financial report for the first half of 2024, highlighting a strategic pivot towards medical aesthetics and biopharmaceuticals. The company’s “medical aesthetics + innovative drug” dual-driven strategy has been instrumental in this transformation. For the…
-
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first half of 2024, reporting a 32.2% year-on-year (YOY) increase in revenues to RMB 1.383 billion, which includes a USD 90 million cooperation payment from its U.S. partner Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK),.…
-
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has reported a decline in its financial performance for the first half of 2024. The company’s overall revenues have dropped by 42.2% year-on-year to RMB 168 million (USD 23.7 million), with profits…
-
MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024H1
•
SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report for the first half of 2024, showing a revenue increase of 44.24% year-on-year to RMB 60.7382 million. Despite an expanded net loss of RMB 201 million, the company has significantly increased its research and development…
-
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
•
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for the first half of 2024, reporting a 17.37% year-on-year increase in revenue to RMB 786 million. The net loss attributable to shareholders narrowed by RMB 352 million compared to the same period last year, reaching…
-
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
•
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company, has released its financial report for the first half of 2024, showing a revenue increase of 17.0% year-on-year to $559 million, excluding the impact of currency exchange rates. The company’s loss for the period was…
-
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
•
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its financial report for the first half of 2024, showcasing a revenue of RMB 204 million. This substantial growth is attributed to the rapid adoption of sunvozertinib, a cutting-edge epidermal growth factor receptor (EGFR) inhibitor, which…
-
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
•
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first half of 2024, with revenues reaching RMB 20.53 billion, marking an 11.12% year-on-year increase. The net profit saw a robust rise, climbing to RMB 7.56 billion, which is a 17.37% increase. Despite a 7.59% YOY…
-
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
•
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for the first half of 2024, reflecting a 46.0% year-on-year increase in revenues, which reached RMB 102.7 million. This growth is primarily attributed to the strong performance of its flagship hypoglycemic agent, HuaTangNing (dorzagliatin tablets). Despite…
-
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
•
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has announced its interim results for 2024 along with significant business updates. The company reported a robust year-over-year (YOY) growth in total revenue, which stood at RMB 3,952.3 million, marking…
-
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
•
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported its financial results for the first half of 2024. The company recorded revenues of RMB 3.0746 billion, marking a 6% increase year-on-year (YOY), and a significant surge in net profits, which rose by 201% YOY…
-
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
•
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million,…
-
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
•
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first half of 2024. The company recorded a modest year-on-year (YOY) increase in revenue, reaching RMB 1.323 billion, which is a 2.5% uptick. More impressively, the adjusted net profit saw a substantial surge of 395.0% YOY,…
-
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
•
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952), has reported its financial results for the first half of 2024. The firm’s revenues experienced a substantial month-on-month increase of 158%, reaching RMB 302 million for the six-month period, primarily propelled by sales of the…
-
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has reported its financial results for the first half of 2024. The Chinese pharmaceutical giant recorded an operating revenue of RMB 20.463 billion, reflecting a 5.31% year-on-year increase,…
-
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
•
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced its 2024H1 financial report through its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The report reveals a significant year-on-year (YOY) increase in total revenues, which stood at RMB 363 million, a rise of…
-
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
•
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the…
-
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate advancements that position the company for future global expansion. For the first half of 2024, BeiGene achieved total operating revenue of USD 1.6808 billion, reflecting a 61.1% year-on-year (YOY) increase. Product revenue surged by 73.0%…
-
Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report
•
Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2696), has reported its financial results for the first half of 2024, with a 9.8% year-on-year (YOY) increase in revenue, amounting to RMB 2.7461 billion. The company has sustained profitability, building…
-
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported its financial results for the first half of 2024, demonstrating robust growth. The company’s revenue reached RMB 787 million, marking a 26.63% increase year-on-year (YOY). The operating profit soared to RMB 472 million, a 44.46%…
-
Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies
•
Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the first half of 2024, reporting a 5.14% year-on-year (YOY) increase in revenues, which reached RMB 139.413 billion. The pharmaceutical industry sector saw a decline in revenue, with a 13.37% YOY decrease to RMB 12.734…
-
CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones
•
CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2616), has reported its interim financial results for 2024, along with key business highlights. For the six months ending June 30, 2024, the company’s revenue reached RMB 254.2 million, which includes RMB 118.3…
-
Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals
•
Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange (SHA: 688177), has reported its financial results for the first half of 2024. The company recorded a 27.85% year-on-year (YOY) increase in revenue, reaching RMB 402.29 million. This growth is likely due to the continued…
-
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim results for the first half of the year, setting a new revenue record with a staggering 477% year-on-year (YOY) increase, reaching RMB 824 million (USD 115.4 million). The lion’s share of this revenue came from…
-
3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength
•
3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530), has reported its interim financial results for 2024. The company’s operating revenue for the period stood at RMB 4.389 billion (USD 614.6 million), reflecting a substantial year-on-year (YOY) increase of 16%. The adjusted EBITDA also…
-
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong Kong Stock Exchange (HKG: 9955), has reported its financial results for the first half of 2024, demonstrating a robust year-on-year (YOY) increase of 17.9%, with total revenues reaching RMB 2.125 billion (USD 298 million). The…
-
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China, has released its unaudited financial report for the first half of 2024. The company’s revenues for the period were on par with the same period in 2023, hitting RMB 8.57 billion (USD 1.2 billion), which…
-
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
•
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and…
-
Jiangsu Hengrui Medicine Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024
•
Jiangsu Hengrui Medicine Co., Ltd, a leading pharmaceutical company based in China with shares traded on the Shanghai Stock Exchange (SHA: 600276), has announced its financial results for the first half of 2024. The company reported a robust revenue of RMB 13.601 billion, reflecting a 21.78% year-on-year (YOY) increase. The…
-
R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first half of 2024, with revenues amounting to RMB 3.114 billion, marking a 7.9% year-on-year (YOY) decline. The innovative drug business contributed RMB 2.203 billion, representing approximately 70.7% of total revenues and reflecting an 8.7% YOY…
-
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported its financial performance for the first half of 2024, along with recent corporate developments. The company is dedicated to offering Contract Research, Development, and…
-
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has reported its financial results for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a significant year-on-year (YOY) increase of 16.81%. The net profits attributable to shareholders have risen…
-
CSPC Pharmaceutical Group Reports Moderate H1 2024 Revenue Growth with Patent Medicines Driving the Increase
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical enterprise, has announced its financial results for the first half of 2024, reflecting a modest year-on-year (YOY) revenue increase of 1.3%, totaling RMB 16.284 billion (USD 2.28 billion). The patent medicine segment demonstrated robust growth, with revenues rising by 4.8%…
-
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
•
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported a remarkable financial performance for the first half of 2024, with revenues jumping 67.6% year-on-year to RMB 1.665 billion (USD 230 million). This…
-
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
•
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its financial performance for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a 16.81% increase year-on-year. Net profits attributable to shareholders have also seen robust growth, climbing to RMB…
-
CSPC Pharmaceutical Group Reports Modest Gains in H1 2024 with Patent Medicines Driving Revenue
•
HONG KONG—CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced its financial results for the first half of 2024, with total revenues reaching RMB 16.284 billion (USD 2.28 billion), reflecting a 1.3% increase year-on-year. The patent medicine business proved to be a significant revenue driver, with sales climbing 4.8% YOY to…
-
CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
•
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim financial report for 2024, revealing a 5.4% year-on-year increase in revenues to HKD 6.05 billion (USD 776.7 million) in constant exchange rate terms. The profit attributable to the company’s owners surged 51.4% year-on-year to approximately…
-
RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales
•
RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving revenues of RMB 742 million (USD 103.9 million), marking a significant 75.59% increase year-on-year. This growth was primarily fueled by heightened sales of its flagship products, telitacicept and disitamab vedotin. The company’s research and development…
-
Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%
•
Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024, generating revenues of RMB 15.87 billion (USD 2.2 billion), marking an 11.1% year-on-year increase and a record high for the company. Net profits surged to RMB 3.02 billion (USD 420 million), reflecting a remarkable 139.7%…
-
Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment
•
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings call, has disclosed a significant transaction: the company has paid Johnson & Johnson’s Janssen division USD 320 million to acquire full royalty rights to the PPAR-delta agonist, seladelpar, a drug for which Gilead obtained global…
-
Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report
•
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results for the second quarter of 2024. Amidst recent speculation about potential implications from the U.S. Biosecure Act, CEO Ying Huang addressed concerns during the earnings call. The U.S. House of Representatives’ committee on China had…
-
Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs
•
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its financial results for the first half and second quarter of 2024. The company achieved a robust 25% year-on-year (YOY) increase in sales, reaching DKK 133,409 million (USD 19,524 billion) in total revenues. This growth was…
-
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
•
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO: 4503), are stepping up their efforts to safeguard the intellectual property of their blockbuster prostate cancer drug, Xtandi (enzalutamide). In a joint legal action with the University of California, the companies have filed a lawsuit…
-
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
•
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has reported robust growth in its Q2 2024 financials, highlighting that previous manufacturing capacity constraints affecting its glucagon-like peptide-1 (GLP-1) drugs have been resolved. The company’s global sales growth surged 37% year-on-year (YOY) in constant currency…
-
Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands
•
Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately 2% operational growth, reaching net revenues of USD 3.8 billion. Both the generics and brands segments experienced a rise of about 2% each during the quarter. The company also reported new product revenues amounting to…
-
BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second quarter of 2024, with total revenues hitting USD 929 million, representing a robust 56% increase year-on-year (YOY). Product sales accounted for USD 921 million of this total, marking a 66% YOY uptick. Operating losses, according…
-
Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development
•
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results for the first half of 2024, showing robust growth. The company recorded revenues of RMB 1.501 billion (USD 209.3 million), marking a 14.22% increase year-on-year (YOY), and a significant surge in net profits to RMB…
-
Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025
•
Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second quarter of 2024, with revenues amounting to USD 1.607 billion, marking a modest growth of 2% year-on-year (YOY) in constant currency terms. This performance aligns with market expectations and keeps the company on track to…
-
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
•
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to €5.4 billion (USD 5.9 billion) over the three-month period. The company’s performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in…
-
Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has released its financial report for the second quarter of 2024, highlighting recent product milestones and corporate developments. The company reported net revenues of USD 100.1 million for Q2’24, marking a 47% increase year-on-year (YOY) at…
-
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
•
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has reported its financial results for the second quarter of 2024. The company posted a 3.1% year-on-year (YOY) increase in constant currency terms, reaching EUR 11.1 billion (USD 12.12 billion) in global group sales for the…
-
Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling
•
Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26…
-
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
•
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY) growth of 24.3%, with revenues reaching JPY 436.18 billion (USD 3.0 billion). This Q1’24 result is notable for being the first to not include revenues from Daiichi Sankyo Espha, the company’s generics unit that was…
-
GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance
•
GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China’s market dynamics being a significant factor in the company’s decision to adjust its annual guidance downward. The company cited the ongoing…
-
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter of the fiscal year 2024, ending June 30, 2024. The company reported a robust performance with a 26.2% increase in global sales, reaching JPY 473,124 million (USD 3.16 billion) compared to the same period last…
-
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
•
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024, showing a 41% year-on-year decrease in total revenues to $305.7 million, in constant currency terms. The company’s oncology products segment reported a 64% increase in revenues to $127.8 million, while the oncology/immune business saw a…
-
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for the second quarter of 2024, showing a robust year-on-year (YOY) growth of 13% in constant currency terms, reaching £7.88 billion ($10.12 billion). The company’s performance was marked by growth across all business units, with the…
-
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
•
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the first quarter of fiscal year 2024, ending June 30, 2024. The company reported a 2.1% increase in global sales year-on-year, reaching ¥1,208 billion ($7.85 billion) at constant exchange rates. Takeda’s Growth and Launch Product portfolio,…
-
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
•
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for the second quarter of 2024, showing a 3% year-on-year (YOY) increase in global revenues in constant currency terms, reaching USD 13.283 billion. This marks the first quarter of positive growth for Pfizer since the peak…
-
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the second quarter of 2024, with global revenues reaching USD 16.1 billion, marking an 11% increase year-on-year when excluding currency impacts. Despite this growth, the company’s stock price declined by 9.81% as investors reacted to the…
-
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
•
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued performance for the first half of 2024, with its financial report indicating a decline in revenues and net profits. Revenues for the period stood at RMB 17.241 billion (USD 2.38 billion), marking an 8.64% year-on-year…
-
Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand
•
Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second quarter of 2024, showing a 2% increase in group sales to €4.5 billion (USD 4.9 billion) on a year-over-year basis, excluding currency impacts. This positive performance was met with a significant stock price increase of…
-
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of 2024, with global sales increasing by 11% year-on-year to $12.2 billion, based on constant exchange rates. The growth was driven in part by the company’s ‘growth portfolio,’ which includes a dozen newer drugs that saw…
-
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
•
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024, demonstrating a solid year-on-year (YOY) growth of 5.6% in constant currency terms, reaching $14.462 billion in revenue. The company’s long-standing blockbuster drug, Humira (adalimumab), continues to face biosimilar competition, resulting in a 28.9% YOY decline…
-
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
•
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported its financial results for the first half of 2024, with group sales remaining stable in Swiss franc terms. However, on a constant exchange rate basis, sales increased by 5% year-on-year to CHF 29.85 billion (USD…
-
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
•
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second quarter and the first half of 2024, demonstrating robust growth. For the six-month period, total revenues increased by 18% year-on-year (YOY) to $25.617 billion, with product sales also experiencing an 18% rise to $24.629 billion.…
-
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
•
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results for the second quarter of 2024, demonstrating a robust year-on-year growth of 10.2% in global net sales, reaching €10.745 billion (USD 11.64 billion) in constant currency terms. This growth was driven by the company’s Pharma…
-
Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second quarter of 2024, demonstrating sustained strong performance akin to the first quarter of this year. Net sales experienced a robust 11% year-on-year (YOY) increase in constant currency terms, reaching USD 12.5 billion for the quarter.…
-
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
•
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged goods manufacturing company, has reportedly discontinued the development of its pipeline epilepsy therapy ADX71149, according to the company’s latest Q2 2024 financials report and information from FiercePharma.com. ADX71149, a positive allosteric modulator (PAM) of metabotropic…
-
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
•
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its financial results for the second quarter of 2024, highlighting a 9.3% year-on-year (YOY) increase in sales, reaching USD 10.4 billion in constant currency terms. The Medical Devices segment was the top performer, marking a 12.1%…
-
Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth
•
Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of 2024, with global sales reaching USD 22.4 billion, reflecting a strong operational growth of 6.6% year-on-year, excluding currency impacts. When adjusting for COVID-19 sales, this growth rises to 7.2%. The company’s innovative medicine segment contributed…
-
Jiangsu Hengrui Medicine Faces FDA Setback with Warning Letter for Quality Control Issues
•
Jiangsu Hengrui Medicine (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a warning letter from the US Food and Drug Administration (FDA), following a Form 483 issued earlier this year in June. The FDA’s notice highlights two principal deficiencies at Hengrui’s facility: the company’s quality control unit…
-
Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial forecast for the first half of 2024. The company anticipates total revenues to amount to RMB 497 million (USD 68.34 million) over the six-month period, marking a significant uptick. Additionally, Abbisko expects to report its…
-
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates. MedBot anticipates a significant year-on-year…
-
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024, showing a slight 0.6% year-on-year (YOY) decrease in group sales to EUR 13.8 billion (USD 14.9 billion), excluding portfolio and exchange rate effects. The pharmaceuticals business segment reported a 3.9% increase in sales, reaching EUR…
-
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
•
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific antibody (BsAb) Mim8 has successfully met the primary endpoints in a late-stage trial for haemophilia A. The trial focused on the reduction of treated bleeding episodes, with once-weekly and once-monthly doses of Mim8 showing reductions…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
-
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
•
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been released, showing a 1.5% year-on-year increase in global revenues at constant exchange rates (CER), reaching JPY 4.3 trillion (USD 27.4 billion). This growth was achieved despite a significant impact from the loss of exclusivity on…
-
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
•
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024, announcing sales of USD 2.5 billion, marking a 6% year-on-year (YOY) increase in constant currency terms. This growth was driven by contributions from all regions. Generics sales experienced a modest 1% YOY increase to USD…
-
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in global sales for the first quarter of 2024, reaching DKK 65.3 billion (USD 9.4 billion) at constant exchange rates (CER). The growth was primarily attributed to strong performances in glucagon-like peptide-1 (GLP-1)-based drugs and obesity…
-
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
•
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first quarter of 2024, with product revenues increasing to USD 87.1 million from USD 62.8 million in the same period of 2023, reflecting a 43% year-on-year (YOY) growth in constant exchange rate terms. The company’s research…
-
BeiGene’s Q1 2024 Revenue Jumps 68% YOY on Strength of Brukinsa and Tislelizumab Sales
•
BeiGene, Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the first quarter of 2024, revealing a total revenue of USD 752 million, marking a 68% year-on-year (YOY) increase. Product revenue specifically soared 82% YOY to USD 747 million. Notably, US sales experienced a significant surge,…
-
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
•
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues for the first quarter of 2024, reaching $1.6 billion, excluding the impact of foreign exchange. This growth was primarily fueled by a robust performance in Women’s Health and Biosimilars segments, which saw revenues surge 12%…
-
Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison
•
Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for the second quarter of fiscal 2024, which concluded on March 31, 2024. The company achieved total revenues of EUR 5.44 billion (USD 5.85 billion), marking a growth of 3% year-on-year (YOY) at constant currency. Siemens…
-
GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first quarter of 2024, with revenues increasing by 10% year-on-year (YOY) to GBP 7.4 billion (USD 9.3 billion), excluding COVID-19-related sales. Core operating profit also showed a robust performance, rising 27% YOY in constant currency terms…
-
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
•
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of 2024 that exceeded expectations, with sales up 26% year-on-year (YOY) to USD 8.77 billion. The growth was driven by the strong performance of the weight-loss drug Mounjaro (tirzepatide), diabetes therapy Zepbound (tirzepatide), Jardiance (empagliflozin) for…
-
Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
•
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of its financial results for the first quarter of 2024. The market responded positively to the underlying portfolio growth and increased profitability, which was amplified by recent operational cost-cutting measures. Despite a challenging comparison with the…
-
Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the first quarter of 2024, reporting a 5.55% year-on-year (YOY) increase in revenues to RMB 1.373 billion (USD 190.3 million). The Chinese pharmaceutical company also saw its net profits surge by 133% YOY to RMB 155…
-
Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval
•
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, which received approval in August 2023 for the treatment of EGFR Exon20ins mutated non-small cell lung cancer in China, has achieved sales of RMB 91.29 million (USD…
-
WuXi AppTec’s Q1 2024 Revenues Affected by COVID-19 Project Exclusion
•
China’s leading Contract Research Organization (CRO), WuXi AppTec (HKG: 2359, SHA: 603259), has announced its financial results for the first quarter of 2024, with revenues reaching RMB 7.98 billion (USD 1.1 billion), marking a slight decrease of 1.8% year-on-year (YOY), excluding COVID-19 commercialization projects. The company’s original customer income stood…
-
Daiichi Sankyo Reports 25.3% Revenue Growth in FY2023, Boosted by Enhertu and Lixiana Sales
•
Japanese pharmaceutical company Daiichi Sankyo has reported a remarkable fiscal year 2023, with revenues increasing by 25.3% to ¥1.602 trillion (USD 10.05 billion) for the 12-month period ended March 31, 2024. The growth was primarily driven by the success of its HER2-targeted antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and…
-
RemeGen’s Q1 2024 Revenues Surge 96.41% YOY, R&D Spending Outpaces Income
•
China-based pharmaceutical company RemeGen (HKG: 9995) has reported its financial results for the first quarter of 2024, with revenues reaching RMB 330 million (USD 45.54 million) for the three-month period, marking a significant increase of 96.41% year-on-year (YOY). However, the company recorded net losses of RMB 349 million (USD 48.2…
-
Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023, with revenues reaching RMB 34.932 billion (USD 4.82 billion), reflecting a robust year-on-year (YOY) growth of 15.04%. Net profits for the medical equipment manufacturer surged to RMB 11.58 billion (USD 1.6 billion), marking an increase…
-
United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships
•
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year 2023, with revenues reaching RMB 11.411 billion (USD 1.57 billion), marking a 23.52% year-on-year (YOY) increase. Net profits for the period were recorded at RMB 1.974 billion (USD 270 million), up 19.21% YOY. The company’s…
-
AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results for the first quarter of 2024, with overall revenues increasing by 19% year-on-year (YOY) in constant currency terms to USD 12.68 billion. Product sales soared 18% YOY, reaching USD 12.18 billion. The company’s business units…
-
Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its first commercial sales with revenues of RMB 39.3 million (USD 5.4 million). The revenues were driven by the COVID-19 vaccine SCB-2019 (CpG 1018/Alum) and the quadrivalent influenza vaccine AdimFlu-S (QIS), which were launched in China…
-
JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
•
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching RMB 173.9 million (USD 24 million), marking a 19.3% year-on-year (YOY) increase. The company’s research and development (R&D) expenditure for the year was RMB 413.6 million (USD 57.08 million), up 1.4% YOY. Sales expenses were…
-
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first quarter of 2024, announcing sales of USD 15.8 billion, an increase of 11% year-on-year (YOY) excluding the impact of foreign exchange rates. The pharmaceutical division contributed USD 14.0 billion to the top line, with a…
-
Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing
•
China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with revenues amounting to RMB 76.6 million (USD 10.57 million), primarily from its core product, HuaTangNing (dorzagliatin tablets), an oral hypoglycemic agent. The revenues were generated from the sale of 251,000 boxes of the drug since…
-
Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches
•
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to €10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to €7.76…
-
Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl
•
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase in revenues for the first quarter of 2024, excluding the impact of foreign exchange, reaching USD 11.9 billion, according to the company’s latest financial report. The U.S. market contributed USD 8.5 billion, marking a 7%…
-
Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics
•
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase in turnover at constant exchange rates (CER) for the first quarter of 2024, reaching CHF 14.4 billion (USD 15.7 billion). The growth was modest but steady, driven by newer medicines and diagnostics, which compensated for…
-
Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales
•
Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a significant year-on-year (YOY) increase of 52.31% in revenues, reaching RMB 2.61 billion (USD 360 million). The Chinese pharmaceutical company also turned profitable, with net profits amounting to RMB 340 million (USD 46.92 million). The company’s…
-
MicroPort MedBot Reports 384.2% YOY Revenue Increase in 2023, Driven by Robotic Surgical Devices
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced its financial results for 2023, reporting a substantial year-on-year (YOY) increase of 384.2%, with revenues reaching RMB 104.6 million (USD 14.43 million). The significant growth is attributed to the sales of its core products: the Toumai endoscopic surgery robot, SkyWalker…
-
Sichuan Kelun Pharmaceutical Reports 12.69% YOY Revenue Growth in 2023 Financial Results
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a leading pharmaceutical company in China, has announced its financial results for 2023, with revenues reaching RMB 21.454 billion (USD 2.96 billion), marking a 12.69% year-on-year (YOY) increase, and a net profit of RMB 2.457 billion (USD 340 million). The company’s research and…
-
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant currency terms during the first quarter of 2024, reaching USD 11.8 billion in sales. The growth was driven by strong performances across all key brands and geographies. The top-selling and growth-driving drugs included hypertension therapy…
-
Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD…
-
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released its financial report for 2023, recording revenues of RMB 52.918 billion (USD 7.3 billion), an increase of 38.3% year-on-year (YOY). Net profits for the company were reported at RMB 8.07 billion (USD 1.11 billion), marking…
-
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues of USD 839.5 million for the year, marking a 34.2% year-on-year (YOY) increase. External revenues from non-cell therapy business reached USD 554.5 million, up 8.9% YOY, while cell therapy sales soared to USD 285 million,…
-
Jiangsu Hengrui Medicine Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released its financial report for 2023, recording RMB 22.82 billion (USD 3.15 billion) in revenues for the year, marking a 7.26% increase year-on-year (YOY). The net profit attributable to shareholders, after adjustments for non-recurring gains and…
-
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
•
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for the first quarter of 2024. The company reported a 4.7% year-on-year (YOY) increase in global sales on an organic basis, reaching USD 10.0 billion. Excluding the impact of reduced demand for SARS-CoV-2 tests, the growth…
-
CSPC Pharmaceutical Posts 1.7% Revenue Growth in 2023, Bolstered by Patent Medicine Sales
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has released its financial report for 2023, recording RMB 31.45 billion (USD 4.34 billion) in revenue for the year, marking a 1.7% increase year-on-year (YOY). The patent medicine business segment contributed RMB 25.637 billion (USD 3.54 billion),…
-
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
•
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing human pharma sales of EUR 20.8 billion (USD 22.1 billion), marking a 10.3% year-on-year (YOY) increase, excluding currency effects. Additionally, animal health sales rose by 6.9% YOY to EUR 4.7 billion (USD 4.9 billion), leading…
-
J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact
•
Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter of 2024, announcing global sales of USD 21.4 billion, marking a 3.9% year-on-year (YOY) increase in operational terms. Both business segments performed well, with innovative medicines seeing a 2.5% YOY rise to USD 13.6 billion.…
-
Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results
•
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its financial report for 2023, showcasing a significant increase in revenues to RMB 225 million (USD 31 million), marking a year-on-year (YOY) growth of 1,347%. This substantial revenue included RMB 124 million (USD 17.1 million) from…
-
Shanghai Junshi Biosciences Reports 3.38% YOY Revenue Growth in 2023 Financials
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in China, has announced its financial results for 2023. The company reported revenues of RMB 1.503 billion (USD 208 million), an increase of 3.38% year-on-year (YOY), primarily driven by sales of its commercialized products. During the…
-
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China, has released its financial report for 2023. The company reported revenues of RMB 5.431 billion (USD 751 million), marking a decline of 24.1% year-on-year (YOY). Profits for the year reached RMB 802 million (USD 110.9…
-
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report for 2023, recording RMB 739 million (USD 102.2 million) in revenues and RMB 672 million (USD 92.9 million) in product sales, marking increases of 18.09% and 18.5% year-on-year (YOY), respectively. The company’s research and development…
-
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
•
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business updates for 2023. The company reported revenues of RMB 218.77 million (USD 27.6 million), marking a 31.12% increase year-on-year (YOY). Product sales accounted for RMB 195.55 million (USD 27 million), with a YOY growth of…
-
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
•
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results for 2023, reporting revenues of RMB 705 million (approximately USD 97.5 million), an increase of 54.86% year-on-year (YOY). This growth was largely driven by the sales of its biosimilar products: Qletli, a biosimilar version of…
-
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
•
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust…
-
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge in the US, has announced its financial results for the full year of 2023. The company reported a significant leap in revenues, reaching USD 89.5 million, which marks an increase of 119.9% year-on-year (YOY). In…
-
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
•
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023 financial results, reporting revenues of RMB 1.083 billion (USD 150 million), reflecting a 40.26% year-on-year increase. This growth was primarily driven by its core products: the fusion protein drug telitacicept and the HER2-targeted antibody drug…
-
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
•
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results alongside a corporate update, revealing a staggering 884% year-on-year revenue increase to RMB 125.9 million (USD 17.4 million). However, net losses widened by RMB 597.2 million, reaching RMB 844.5 million. Notably, research and development (R&D)…
-
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its financial performance for 2023, along with recent business updates. The group reported a total revenue of RMB 6.143 billion (USD 850 million), marking a 2.7% year-on-year (YOY) growth. Their oncology, cardiovascular, central nervous system (CNS),…
-
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced its financial report for 2023. The company reported a 33.9% year-on-year (YOY) increase in revenue, reaching RMB 336 million (USD 46.5 million), with gross profits surging 41.8% to RMB 223 million (USD…
-
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report for 2023, highlighting a total revenue growth of 5.9% year-on-year (YOY) to RMB 222 million (USD 30.7 million). This figure includes product sales amounting to RMB 194 million (USD 26.8 million). The company’s marketing and…
-
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
•
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for 2023, recording revenues of RMB 345.2 million (USD 47.7 million), a decrease of 67% year-on-year (YOY). This decline is primarily attributed to the reduced demand for COVID-19 vaccines, resulting in a RMB 253.2 million refund.…
-
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
•
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has released its financial report for 2023, showing a year-on-year (YOY) increase of 11.6% in revenues to RMB 17,034.3 billion (USD 2.35 billion). The company’s net profits reached RMB 3.57 billion (USD 495 million),…
-
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has released its financial report for 2023, recording RMB 41.4 billion (USD 5.73 billion) in revenues, marking a -5.81% year-on-year (YOY) decrease. However, excluding the loss of COVID-19 product sales, the figure shows…
-
National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023
•
The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling Inspection Annual Report (2023),” providing a comprehensive overview of the drug quality surveillance conducted in the past year. The report details the testing of 132 drug varieties, comprising 74 chemical drugs, 43 patented traditional Chinese…
-
Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5%…
-
Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting a 7.7% year-on-year (YOY) increase in revenues to RMB 10.104 billion (USD 1.4 billion). The Chinese pharmaceutical company’s net profits reached RMB 3.278 billion (USD 453.7 million), marking a 26.9% YOY growth. Research and development…
-
Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of RMB 1.54 billion (USD 213 million), marking a substantial year-on-year increase of 91.6%, primarily driven by licensing agreements. The company recorded an annual loss of RMB 450 million (USD 62 million), representing a 24.4% reduction…
-
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
•
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled its financial performance for 2023, reporting revenues of RMB 2.124 billion, marking a significant increase of 114.4% year-on-year (YOY), primarily driven by its antibody…
-
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13…
-
Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials
•
Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues of RMB 5.395 billion (USD 749 million), marking a 67.8% year-on-year (YOY) increase. The company achieved its first profitable full year with net profits reaching RMB 546 million (USD 76 million). The strong financial performance…
-
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
•
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results, achieving revenues of RMB 7.816 billion (USD 1.09 billion), reflecting a year-on-year (YOY) growth of 13.8%. Net profits rose to RMB 1.952 billion (USD 271 million), an increase of 17.7% YOY. The company’s core biologic…
-
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
•
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report, revealing a robust revenue growth of 36.2% year-on-year (YOY) to RMB 6.21 billion (USD 862 million). Product sales constituted RMB 5.73 billion (USD 796 million), marking a 38.4% YOY increase. Despite reporting a loss of…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
-
China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results for 2023, with revenues reaching HKD 10.53 billion (USD 1.35 billion), marking a 15.8% year-on-year increase. The net profit stood at HKD 2.04 billion (USD 260.8 million), up by a modest 0.2% year-on-year. The company…
-
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
•
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net…
-
Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs
•
Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue of RMB 4.526 billion (USD 629 million), marking a staggering 440% year-on-year increase. The company, based in China, posted its first annual profit with net earnings reaching RMB 1.942 billion (USD 269.7 million). Innovative drugs…
-
Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
•
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and full year of 2023, along with key business highlights. The company reported licensing income of USD 35.2 million and cooperation income of USD 249.8 million, primarily attributed to milestone payments related to the Carvykti (ciltacabtagene…
-
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
•
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global net sales for the fiscal year 2023, amounting to €21.0 billion ($23.0 billion). This contraction was partially attributed to the adverse impact of foreign exchange rates. The company’s Healthcare division, however, posted a 2.7% increase…
-
Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies
•
Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting an 8.2% year-on-year (YOY) increase in revenue to DKK 19.912 billion (USD 2.88 billion). The company is now under the leadership of CEO Charl van Zyl, who took over from Deborah Dunsire in October 2023.…
-
Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
•
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of declining sales that culminated in a 1.2% year-on-year (YOY) drop in constant currency and portfolio-adjusted terms, reaching €47.6 billion (USD 51.7 billion). The Pharmaceuticals segment generated €18.1 billion (USD 19.6 billion) with a 0.4% decline…
-
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit forecast, anticipating a minimum profit of RMB 500 million (USD 72.4 million) in 2023, marking the company’s first profitable year. This forecast is attributed to the sustained sales growth of its products Hanquyou (trastuzumab injection,…
-
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced a forecast for its 2023 financial performance along with key business updates. The company anticipates generating sales within the range of RMB 330 million to RMB 340 million for the year, reflecting…
-
HutchMed’s 2023 Financials Show 102% YOY Revenue Growth and Robust Collaboration with Takeda
•
HutchMed (HKG: 0013, NASDAQ: HCM), a China-based biopharmaceutical company, has released its financial report for 2023, recording a significant increase in revenue to USD 838 million, marking a 102% year-on-year growth calculated on a constant currency basis. The company’s net profits reached USD 101 million, attributed to its collaboration with…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial results for 2023, along with updates on product highlights and corporate developments. The company reported total product revenues of USD 266.7 million for the year, marking a 31% year-on-year growth at constant exchange rates. This…
-
BeiGene Reports Record Revenues and Rapid Growth in Q4 and Full Year 2023 with Continued Expansion
•
BeiGene (NASDAQ: BGNE), a China-based biopharmaceutical company, has presented its financial results for the fourth quarter and full year of 2023, along with key business highlights. The company reported continued rapid global growth, with record total revenues reaching USD 634 million in the fourth quarter and USD 2.5 billion for…
-
Organon Reports Q4 2023 Revenue Growth Driven by Women’s Health and Biosimilars
•
Organon (NYSE: OGN), the U.S.-based pharmaceutical company, has reported its fourth-quarter 2023 financial results, revealing a 3% year-on-year increase in global revenues, reaching USD 6.3 billion in constant currencies. The company’s performance showed marked improvement, with Q4 revenues climbing 8% year-on-year to USD 1.6 billion. Breaking down Q4 performance by…
-
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week, revealing a 6% year-on-year increase in annual global revenues, reaching USD 45.8 billion at constant exchange rates. Oncology revenue surged by 21%, while cardiovascular, renal, and metabolism (CVRM) sales rose 18%. Respiratory and immunology (R&I)…
-
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
•
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with total product sales remaining unchanged at USD 26.9 billion. Amid a broad decline in demand for COVID-19 treatments, the company’s antiviral Veklury (remdesivir) sales could not offset the downturn, although HIV sales increased by 6%…
-
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
•
Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first three quarters of its fiscal year 2023, ending December 31, 2023. The corporation reported a year-on-year (YOY) increase of 2.1% in global revenues, reaching JPY 1,189 billion (USD 8 billion) over the nine-month period. Astellas’…
-
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
•
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining flat at USD 26.9 billion. The company’s financials were affected by a widespread downturn in demand for COVID-19 treatments, as its antiviral Veklury (remdesivir) sales offset growth in other areas. HIV sales reached USD 18.2…
-
Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
•
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual sales of USD 26.9 billion, reflecting a substantial 9% year-on-year (YOY) increase, primarily driven by volume growth. In an earnings call, CEO Robert Bradway highlighted that a remarkable 18 of the company’s medicines achieved record…
-
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
•
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20% year-on-year (YOY) increase in revenue, reaching USD 34.1 billion, as detailed in their Q4 2023 report released this week. This growth was substantially driven by the company’s metabolism drugs, indicating a recovery from the COVID-19…
-
Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales
•
Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing over RMB 1.6 billion (USD 219 million) in product sales for Q4 2023, marking a 65% year-on-year (YOY) increase. In the final quarter of the year, Innovent’s PD-1 inhibitor, Tyvyt (sintilimab injection), maintained strong market…
-
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
•
Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the first three quarters of its fiscal year 2023, concluding on December 31, 2023. The company has experienced a modest 2.1% year-on-year (YOY) increase in global revenues, totaling JPY 1,189 billion (USD 8 billion) for the…
-
Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth
•
US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for the first quarter of the fiscal year 2024, ending December 31, 2023. In constant currency terms, sales increased by 1.6% year-on-year (YOY) to USD 4.7 billion. Breaking down the figures by business segment, BD Medical,…
-
AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability
•
AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline at constant currency rates, as the company grapples with the erosion of its flagship immunosuppressant, Humira (adalimumab). While the neuroscience and aesthetics segments showed resilience with revenue increases of 18.5% and 0.9%, generating $7.7 billion…
-
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding foreign exchange effects, totaling $45.0 billion, according to its recently released financial report. The company’s global sales were bolstered by a 4% increase in in-line products, generating $34.3 billion, and a remarkable 76% surge in…
-
Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels
•
Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the first quarter of the fiscal year 2024, concluded on December 31, 2023. On a currency-adjusted basis, sales increased by 5.7% to EUR 5.18 billion (USD 5.6 billion). When excluding the impact of COVID-19-related sales, the…
-
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest 1% year-on-year (YOY) increase in global sales at constant exchange rates (CER) to CHF 58.7 billion (USD 68.5 billion). This growth was primarily due to a 6% YOY expansion in the pharmaceutical business to CHF…
-
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
•
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for the fourth quarter and the full year of 2023, showcasing a remarkable performance. The company’s revenues reached DKK 232.3 billion (USD 33.75 billion), reflecting a 36% year-on-year growth in constant currency terms. The standout product…
-
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. The company’s global revenues for the 12-month period reached EUR 43.07 billion (USD 47 billion), marking a 5.3% increase year-on-year in constant currency terms. Key drivers of this…
-
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the 9-month period ended December 31, 2023, reporting a revenue of JPY 3.2 trillion (USD 21.9 billion) with a 0.0% growth at constant exchange rates (CER). The company’s performance was impacted by declines in oncology, neuroscience,…
-
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. In Q4, MSD generated USD 14.6 billion in sales, marking a 6% year-on-year increase, with growth expanding to 13% when excluding the impacts from…
-
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled an impressive 2023 performance forecast following its recent listing on the Hong Kong stock exchange. The company anticipates a more than 100% surge in…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales for the last financial year, amassing USD 45.4 billion—a 10% year-on-year (YOY) increase in constant currency terms, as per the 2023 financials released this week. This achievement marks Novartis’s inaugural annual report following the strategic…
-
Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China, has released its financial forecast for 2023. The company anticipates generating RMB 1.541 billion in revenues, marking a 6.02% year-on-year (YOY) increase. Junshi Biosciences’ research and development expenses for the period are estimated at RMB…
-
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
•
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week, amounting to USD 58.5 billion, following a 41% year-on-year (YOY) decrease in operational terms. This substantial drop reflects the diminishing sales of the SARS-CoV-2 vaccine Comirnaty and the antiviral treatment Paxlovid. The reported figures align…
-
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth forecast for its subsidiary Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), in which it holds a 40.32% stake. MicroPort Endovascular is anticipated to achieve revenues within the range of RMB 1.17-1.2 billion (USD 168-238…
-
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
•
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans to shut down two of its factories, one in the US and another in China. The report states that this decision is made “in the context of current market dynamics” and is part of efforts…
-
Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued a forecast for its 2023 performance, warning that net profits are expected to be within the range of RMB 1.2-1.35 billion (USD 169-190 million), marking a significant year-on-year (YOY) decrease of 74.66%-71.49%. The company’s sales…
-
Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline
•
US healthcare company Abbott (NYSE: ABT) has released its financial results for the fourth quarter and full year of 2023. The company’s Q4 global sales increased by 2.1% year-on-year (YOY) in constant currency terms to USD 10.24 billion, although for the full year, sales declined by 6.2% to USD 40.1…
-
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
•
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for the fourth quarter and full year of 2023. Fourth-quarter global sales increased by 7.2% excluding currency impacts to USD 21.4 billion, while full-year revenues rose by 7.4% year-on-year (YOY) to USD 85.16 billion. Both the…
-
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for the fiscal year ending December 31, 2023. The company expects to report revenues within the range of RMB 124-126 million (USD 17.2-17.5 million), a significant increase compared to the RMB 12.8 million (USD 1.78 million)…
-
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
•
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen Inc. (NASDAQ: SGEN), with the deal set to close today. The US pharmaceutical giant had to make concessions to address the US Federal Trade Commission’s (FTC) concerns over…
-
WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall
•
WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December 4, 2023, following an investor presentation that disclosed the contract development manufacturing organization (CDMO) industry’s growth has slowed to single digits, down from over 15% in recent years. The company’s business update revealed that its…
-
Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services
•
Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results for the first half of 2023, ending September 30, reporting revenues of RMB 12.956 billion. This represents a year-on-year increase of 12.7%, driven by robust growth in its pharmaceutical self-operated business as well as its…
-
Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials
•
Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published its financial results for the third quarter of 2023. The company reported revenues of RMB 3.9278 billion (USD 542 million) for the nine months ending September 30, 2023, marking an impressive 84.0% year-on-year (YOY) increase.…
-
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
•
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter of 2023. The company reported a 13.5% decrease in sales, amounting to USD 8.8 million. Despite this downturn, several positive developments indicate a promising outlook for the company in the near future. Revenue Generator and…
-
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the third quarter and the first three quarters of 2023. The company reported a 7% year-on-year (YOY) increase in revenues in constant currency terms for the three-month period, reaching DKK 4.952 billion (USD 709 million). For…
-
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
•
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023, revealing a 4.1% year-on-year (YOY) decline in organic sales, totaling EUR 5.2 billion (USD 5.5 billion) for the three-month period. The results highlight a challenging environment, with only the Healthcare division showing growth. The Healthcare…
-
BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the third quarter of 2023. The biotechnology company reported total revenues of USD 781 million, with global product sales reaching USD 595 million, marking year-on-year (YOY) increases of 102% and 70%, respectively. Net profits for the…
-
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines,…
-
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
•
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023, revealing global sales of EUR 35.8 billion (USD 38.3 billion) between Q1 and Q3, marking a 3.2% year-on-year (YOY) decline. Despite this, the company confirmed its 2023 guidance of EUR 48.5 billion to EUR 49.5…
-
Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call
•
US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third quarter of 2023. The company reported global net sales of USD 3.93 billion, marking a 1% year-on-year (YOY) increase in constant currency terms. Geographical Sales BreakdownViatris Inc.’s sales performance varied by region. Developed and Emerging…
-
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
•
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third quarter of 2023, showcasing a significant year-on-year (YOY) increase in global sales. The company’s revenues rose by 155% to USD 40.1 million, reflecting the success of its anti-anemia drug for chronic kidney disease (CKD), Evrenzo…
-
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing a 33% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 166.4 billion (USD 23.7 billion) over the first nine months. The company identified diabetes care and obesity care as the key growth drivers,…
-
Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth
•
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its product sales for Q3 2023, which exceeded RMB 1.6 billion (USD 219 million), marking a 45% increase year-on-year (YOY). The company’s PD-1 inhibitor, Tyvyt (sintilimab injection), continued to show strong market performance, and there was…
-
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
•
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio…
-
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
•
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023, showing a 1% year-on-year (YOY) decrease in sales to USD 1.519 billion in constant currency terms. The company’s performance was marked by a 7% decline in Women’s Health sales to USD 418 million, a 10%…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
-
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
•
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for the six months ended September 30, 2023, reaching JPY 726.3 billion (USD 4.8 billion), according to the company’s financial report published this week. This growth was driven by a combination of factors, including the depreciation…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials
•
Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half (H1) of fiscal 2023, which ended on September 30, 2023. The company reported a modest year-on-year (YOY) increase in global revenues, reaching JPY 767.14 billion (USD 5.1 billion), marking a growth of just 0.6%. Performance…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
•
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY) increase in global sales, reaching USD 6.5 billion. This growth comes despite a 3% decrease in net selling price, primarily fueled by an impressive 11% increase in volume. Notably, this marks the company’s fourth consecutive…
-
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
•
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year (YOY) decline in net revenues for the first nine months of the year, amounting to USD 40.0 billion. The decrease was attributed to underperformance across most business areas, with the exception of neuroscience, which reported…
-
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
•
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for the Q2 2024 fiscal year ended September 30, 2023. The company reported consolidated revenues of USD 828 million for the quarter, marking a 9% year-on-year (YOY) increase. This growth was primarily driven by robust generic…
-
Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for the Q1-Q3 2023 period. The company generated RMB 27.3 billion (USD 3.74 billion) in revenues during the first three quarters, marking a 17.2% year-on-year (YOY) increase. This growth underscores Mindray’s strong market position and effective…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
-
Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9…
-
Takeda’s Global Revenues Grow: Strong Performance in Plasma Therapies and Gastroenterology
•
Japan-based pharmaceutical giant Takeda (TYO: 4502) has released its financial results for the 6-month period ending September 30, 2023, with global revenues hitting JPY 2.1 trillion (USD 14.0 billion). This represents a 6.4% year-on-year (YOY) increase in reported terms, or a more modest 1.4% growth at constant exchange rates (CER).…
-
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign exchange impact, to USD 11.0 billion for Q3 2023, as detailed in the company’s recently released financial report. The downturn was primarily attributed to a significant 41% YOY drop in sales of the multiple myeloma…
-
Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline
•
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory…
-
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
•
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since the company sharpened its focus on innovative medicines following the spinoff of Sandoz (SWX: SDZ) earlier this month. The financials reveal a robust performance with net sales reaching USD 34.0 billion for the first nine…
-
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced demand for COVID-19 products impacted global growth, resulting in a 1% year-on-year (YOY) increase at constant exchange rates over the first nine months, with total sales amounting to CHF 44.1 billion (USD 49.4 billion). Excluding…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
•
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global sales of USD 63.7 billion for the first nine months of the year. This marks a 7.5% year-on-year (YOY) expansion in operational terms, reflecting robust performance across both of the company’s main business segments. Segment…
-
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
•
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a robust 33% year-on-year (YOY) increase in sales at constant exchange rates (CER) from Q1 to Q3 this year. Notably, Q3 alone saw a significant 38% YOY jump, indicating a strong market reception for the company’s…
-
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
•
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a decrease in demand for COVID-19 solutions. The new revenue projection falls between USD 58.0 billion and 61.0 billion, a significant adjustment from the previously anticipated range of USD 67.0 billion to 70.0 billion as reported…
-
Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
•
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report for the first half of 2023. The company recorded revenues of RMB 15.28 billion (USD 2 billion), marking a 0.5% increase year-on-year (YOY). Innovative drugs contributed significantly to the total revenues, generating RMB 3.86 billion…
-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report for the first half of 2023, highlighting strong revenue growth and significant advancements in its clinical pipeline. The company recorded revenues of HKD 5.989 billion (USD 766 million) and net profits of HKD 1.124 billion…
-
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
•
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has released its 2023 interim report, showcasing significant financial growth. The company reported revenues of RMB 165.9 million, marking a 33.0% increase year-on-year (YOY). Net profits also saw a substantial rise, surging by 213.7% YOY to…
-
Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing a robust performance in the first half of the year. The company reported revenues of RMB 3.379 billion (USD 466 million), reflecting a 25.2% year-on-year (YOY) increase. Notably, sales of innovative drugs accounted for 71%…
-
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
•
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first half of 2023, highlighting significant revenue generated by envafolimab, a programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The product has been covered under 32 city-level insurance schemes (HuiMinBao) and has seen rapid uptake,…
-
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for the first half of 2023, showcasing impressive revenue growth of 19% year-on-year (YOY) to USD 493 million. The company also reported a 13% reduction in losses, totaling USD 220 million. This performance highlights the company’s…
-
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first half of 2023, recording revenues of RMB 21.09 million (USD 2.89 million), a decrease of 96.7% year-on-year (YOY). The contributions from China and overseas markets were RMB 17.93 million and RMB 3.16 million, respectively. The…
